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Abstract

Ductal carcinoma in situ (DCIS) is currently considered an early and localized form
of ductal breast cancer stemming from the epithelial ductal cells. These lesions are largely
heterogenous, categorized by their morphologies, amount of necrosis, and stromal changes. Even
though 10-year mortality rate for DCIS is 1-2.6% while that of early invasive breast cancer is 710%. Yet, current recommended treatment for DCIS is breast-conserving surgery and radiation or
mastectomy – the same treatment regimen recommended for early invasive breast
cancer. This assumes that all DCIS will progress to invasive breast cancer if left untreated.
However, mounting evidence indicates that a significant number of DCIS would remain indolence
and never progress to invasive cancer. Current risk stratification is based on grade and hormone
receptor (estrogen and progesterone) status. While the underlying mechanisms for DCIS to
invasive cancer progression are not well understood, an improvement in the quantification of
cellular morphology, the extracellular matrix and the metabolism modification of the
tumor microenvironment could provide a more accurate and objective prognostication
and
treatment
recommendations.
DCIS
is
currently
graded
manually
by
a surgical pathologist using a representative number of areas on the slide. This risks grading bias
between different pathologists. By using an automated software to measure quantifiable
attributes such as nuclear density, size, and degree of variation of all areas of DCIS on the slide,
we can have a more uniform and objective scoring system that would have minimal bias and
variation. In addition, we will quantify heterogeneity of collagen arrangement, collagen fiber
profile in the stroma as well as the metabolic modifications in the tumor microenvironment of “low
risk” vs “high risk” DCIS to determine factors that could provide us with a better prognostication
system.

Methods

Results

1. DCIS cases were selected and stratified based on HER2 and estrogen receptor (ER)
status:

HER2 and ER Status are Related to Ductal Cell Heterogeneity
Hayward et al., proposed that ducts could be accurately sorted into DCIS grade by the area of
their nuclei. Following their criteria, we determined the percentage of each DCIS grade in
each group. The criteria for each DCIS grade are as follows:
Normal Duct < 20 µm
DCIS Grade 2: 30 – 40 µm
DCIS Grade 1: 20 – 30 µm
DCIS Grade 3: > 40 µm

hi

Group A = HER2-/ER+; least aggressive
Group B = HER2+/ER+; slightly more aggressive than HER2+/ERGroup C = HER2+/ER-; more aggressive than HER2-/ER+
Group D = HER2-/ER-; "triple negative", most aggressive receptor status
hi

A breast surgical pathologist, Dr. David Wagner, was consulted to score the DCIS slides.
Slides were cut, stained, digitally scanned, and assessed in QuPath (software for whole
slide image analysis of H&E slides and automated nuclear quantification). Regions of
interest (ROIs, individual ducts) were manually selected using the software’s polygon tool
(Fig 2a), followed by the automatic quantification of the nuclear data for the ROI (Fig 2b).
Data from QuPath was exported to Microsoft Excel. Single factor ANOVAs and ad hoc
student t-tests were used for statistical analysis.
Endogenous fluorescence from the metabolic intermediates, NADH and FAD, were
acquired at the MITI Research Core.
Using FIJI (NIH ImageJ), ductal ROIs were selected and the optical redox ratio (ORR,
FAD/(NADH+FAD)) was calculated. (Fig 2c)
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Figure 4: The more aggressive DCIS (Group B and D) are comprised of mostly normal and
Grade 1 DCIS while the least aggressive DCIS (Group A) has the grades more evenly distributed.
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Figure 5: Groups A and C showed a
statistically higher than Group B (p < .01)
NADH intensity. There was no statistical
difference between Groups A and C, or
any group with Group D (p > .05).
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DCIS comprises of approximately 25% of all breast
cancer cases in the United States. Incidence of DCIS have
increased over the past several decades due to the
widespread use of mammographic screening. The
standard treatment for DCIS is lumpectomy followed by
radiation therapy, or mastectomy alone. However, clinical
trials are ongoing to determine new risk stratification
systems that could identify low risk DCIS cases that can
omit or receive less invasive treatment.
One difficulty when assigning a standard treatment for
DCIS is its large heterogeneity. DCIS is graded into 3
groups: low, intermediate, and high grade. These
categories are judged by pathologists on morphology (Fig
1a), amount of necrosis, and tumor grade. Figure 1a
demonstrates the four morphological architectures.
Studies have suggested that micropapillary has been
correlated to the lowest risk of recurrence and
metastasizing, while a presence of necrosis indicates
higher risk.
Other characteristics have been identified as potential
indicators for high grade DCIS. Nuclear size and density
are factors that change in most cancer cases. Tumor
infiltrating lymphocytes (TILs) are the immune response to
DCIS and are observed as a potential indicator of DCIS
risk. Lastly, hormonal receptors, particularly HER2
receptor positivity, have been indicated as an early
indicator for DCIS becoming high grade. All these factors
likely play some role in DCIS grade, but for this study, we
will look particularly at nuclear size, density, and optical
redox ratio.
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Figure 2: (a) ROI selected from H&E-stained slide from nuclear quantification. (b) QuPath runs
nuclear recognition software and highlights identified regions. This is exported to Excel for further
data analysis. (c) FIJI analysis quantifies NADH/FAD luminescence from selected ROI.

Results
HER2 and ER Status are Related to Differences in Cell Density and Nuclear Area
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Figure 1:
DCIS morphology
with H&E- stained
samples (above).
Progression
of
breast duct from
normal to invasive
carcinoma (below).
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Conclusion

• Nuclear density would be expected to increase with the progression of DCIS. Our data showed
group D ("triple negative", most aggressive receptor status) has the highest density compared to
the other three groups. In addition, Group B had significantly higher density than C which is
expected since HER2+/ER+ cancer are known to be more aggressive than HER2+/ER-.
• Interestingly, our data showed a significant decrease in nuclear size associated with increasing
degree of aggressiveness (Group D) of the DCIS with the most aggressive group has a distinct
significantly lowest nuclear area.
• We predicted greater heterogeneity in the Group D ducts, the most aggressive receptor status. The
greatest heterogeneity was observed in the least aggressive receptor status samples.
• There were no gross differences in cellular metabolism measured using ORR.
• Ongoing studies will increase sample sizes, stratify samples by recurrence, and included
measurements of extracellular matrix changes (collagen density) to better resolve recurrence risk
in individual with DCIS.
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Figure 3: (a) We predicted area would increase with receptor status associated
aggressiveness because of the rapid-reproducing nature of cancer. Nuclei in Group D (most
aggressive receptor status) were significantly smaller than all other groups. Group B (more
aggressive) also showed a smaller nuclei than Groups A and C nuclei. (b) Nuclear density in
Group D (most aggressive receptor status) was significantly larger than all other groups. Group
B (more aggressive) also showed a larger nuclear density than Groups A and C nuclear
densities.
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